News

Location:Home > News > Industry news
Oral OTEZLA® (Apremilast) Monotherapy...
2014-07-28

Clinically meaningful improvements in enthesitis, dactylitis and physical function with OTEZLA seen at week 16 and were sustained for up to 52 weeks of treatment PALACE 4 is the first and only large...

Merck Strengthens Commitment to Chinese ...
2014-07-28

Merck, a leading company for high-tech products in the pharmaceutical and chemical sectors, today reiterated its commitment to investments in the Chinese market, strengthening a major pillar of its...

FDA approves new product to treat rare...
2014-07-28

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with...

Merck Announces Data from...
2014-07-28

known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND® (aprepitant) in the prevention of ...

Forest to Present Aclidinium Bromide and...
2014-07-28

NEW YORK (BUSINESS WIRE) Forest Laboratories, Inc (NYSE: FRX) today announced that they will present data related to aclidinium bromide and roflumilast at the American Thoracic Society (ATS)...